Johnson & Johnson (NYSE:JNJ) Reaches New 52-Week High – Should You Buy?

Johnson & Johnson (NYSE:JNJ) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $275.53 and last traded at $275.6790, with a volume of 1054323 shares traded. The stock had previously closed at $271.11.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA clearance expands the robotic-surgery opportunity. The FDA cleared J&J’s AI-powered MONARCH QUEST 3 bronchoscopy update, adding enhanced planning, navigation, imaging and procedure-review capabilities. The approval could broaden adoption of J&J’s robotic lung-diagnostics platform and reinforce its MedTech growth strategy. J&J secures FDA clearance for MONARCH QUEST 3
• Positive Sentiment: Recent financial performance exceeded expectations. Second-quarter revenue rose 6.6% year over year to $25.31 billion, above the $25.06 billion consensus estimate. Adjusted EPS of $2.90 also beat expectations of $2.84, and J&J raised its 2026 outlook to $11.60–$11.75 in adjusted EPS. Johnson & Johnson earnings and outlook
• Positive Sentiment: New pharmaceutical products may offset Stelara pressure. J&J’s immunology and neuroscience franchises are emerging as growth drivers as newer medicines help mitigate the impact of Stelara’s loss of exclusivity. The company also raised its quarterly dividend 3.1% to $1.34, marking its 64th consecutive annual increase and supporting its income-investor appeal. J&J’s growth franchises
• Neutral Sentiment: Call-option volume was 29% above average, indicating increased short-term bullish positioning but potentially greater volatility. Analysts remain generally constructive, with a consensus “Moderate Buy” rating, although the median recent price target of $263 is below the stock’s recent trading range.
• Negative Sentiment: Executive Vice President Jennifer Taubert sold 15,000 shares for approximately $3.95 million, reducing her position by 7.16%. Reports also show no open-market insider purchases and multiple executive sales over the past six months, a trend that could weigh on sentiment even though such transactions may reflect personal financial planning. SEC insider transaction filing

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company raised their price objective on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Guggenheim boosted their target price on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $268.22.

Johnson & Johnson Stock Performance

The firm has a market cap of $660.01 billion, a price-to-earnings ratio of 31.70, a P/E/G ratio of 2.48 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm has a fifty day simple moving average of $253.21 and a two-hundred day simple moving average of $241.91.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts expect that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 63,972 shares of company stock worth $16,245,605. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Blueline Advisors LLC purchased a new position in Johnson & Johnson during the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $26,000. DecisionPoint Financial LLC raised its holdings in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC lifted its position in Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after purchasing an additional 49 shares during the period. Finally, Semmax Financial Advisors Inc. grew its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.